The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Will Be The Estimated Market Size Of The Multiple Sclerosis Drugs Market By 2030?
The multiple sclerosis drugs market has observed rapid expansion in recent years. This market is projected to enlarge from $33.46 billion in 2025 to $37.67 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.6%. Historically, this expansion has been linked to factors such as the restricted availability of MS treatments, the increasing prevalence of multiple sclerosis, greater awareness among patients and physicians, reliance on interferon-based therapies, and the growth of hospital and retail pharmacy networks.
The multiple sclerosis drugs market size is anticipated to experience substantial expansion over the forthcoming years. It will grow to $61.43 billion in 2030 at a compound annual growth rate (CAGR) of 13.0%. This growth throughout the forecast period is fueled by factors such as the creation of innovative monoclonal antibodies, the broader availability of oral disease-modifying therapies, the incorporation of personalized medicine into MS treatment, increased investment in research and development for new therapeutic options, and the wider uptake of digital health monitoring and telemedicine platforms. Key developments expected during the forecast period involve the increasing use of disease-modifying therapies for multiple sclerosis, the evolution of personalized and targeted MS treatment strategies, an expansion of both hospital and retail pharmacy distribution networks, a growing inclination towards oral and parenteral methods of drug delivery, and the introduction of new immunomodulators, immunosuppressants, and monoclonal antibodies.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2817&type=smp
Which Major Factors Are Contributing To The Development Of The Multiple Sclerosis Drugs Market?
The expansion of the multiple sclerosis drugs market receives assistance from both governmental and non-governmental organizations. These entities fund various initiatives and programs, aiming to improve the quality of life for individuals living with multiple sclerosis (MS). As an illustration, the government of Alberta, collaborating with Canada’s Department of Economic Development, Trade, and Tourism, allocated $1 million to the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo). This investment was made to support research and innovations designed to enhance the understanding and treatment of MS disease. CanProCo operates as an initiative to consolidate the efforts of almost 50 MS researchers from diverse disciplines throughout Canada. The project subsequently secured additional funding from the Canada Brain Research, Biogen Canada, the MS Society of Canada, and Hoffmann-La Roche Limited (Roche Canada), collectively raising a total of $10 million. Such consistent financial support from government and non-government organizations significantly drives the growth of the multiple sclerosis drugs market.
What Segment Types Are Included In The Multiple Sclerosis Drugs Market Analysis?
The multiple sclerosis drugs market covered in this report is segmented –
1) By Drug Class: Immunomodulators, Immunosuppressants, Interferons, Other Drug Classes
2) By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Stores
3) By Route Of Administration: Oral Drugs, Parenteral Drugs
Subsegments:
1) By Immunomodulators: Glatiramer Acetate, Fingolimod, Teriflunomide, Dimethyl Fumarate
2) By Immunosuppressants: Natalizumab, Alemtuzumab, Ocrelizumab
3) By Interferons: Interferon Beta-1a, Interferon Beta-1b
4) By Other Drug Classes: Sphingosine 1-Phosphate Receptor Modulators, Monoclonal Antibodies, Other Emerging Therapies
Which Trends Are Expected To Shape The Multiple Sclerosis Drugs Market?
Leading companies active in the multiple sclerosis drugs market are committed to developing innovative solutions aimed at improving treatment efficacy, enhancing the quality of life for patients, and addressing the diverse needs of individuals living with multiple sclerosis. These innovative solutions refer to new and creative approaches, products, or technologies designed to effectively tackle specific challenges or problems. For instance, in September 2024, Genentech, a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) granted approval for Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) to treat both relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo is notable as the first and only subcutaneous injection, administered by healthcare professionals, that is given twice a year and requires approximately 10 minutes, thereby offering individuals with MS additional treatment options.
Who Are The Major Companies Operating In The Multiple Sclerosis Drugs Market?
Major companies operating in the multiple sclerosis drugs market are Biogen Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Bayer HealthCare LLC, Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Acorda Therapeutics Inc., EMD Serono Inc., AbbVie Inc., Bayer Schering Pharma AG, Bristol-Myers Squibb Company, Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Opexa Therapeutics Inc., Receptos Inc., Synthon Pharmaceuticals Inc., TG Therapeutics Inc., Alkermes plc, Amgen Inc., Atara Biotherapeutics Inc., Celgene Corporation, Genzyme Corporation
Access The Complete Multiple Sclerosis Drugs Market Report:
https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-drugs-global-market-report
Which Geographic Region Represents The Largest Multiple Sclerosis Drugs Market Share?
North America was the largest region in the global multiple sclerosis drug market in 2025. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple sclerosis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Multiple Sclerosis Drugs Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=2817&type=smp
Browse Through More Reports Similar to the Global Multiple Sclerosis Drugs Market 2026, By The Business Research Company
Musculoskeletal Disorder Drugs Market Report 2026
Macular Degeneration Treatment Market Report 2026
Central Nervous System Drug Market Report 2026
https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model